MP51-14 INTERMEDIATE TO LONG TERM RENAL FUNCTIONAL OUTCOME IN PEDIATRIC PATIENTS WITH PREEXISTING CHRONIC KIDNEY DISEASE FOLLOWING ILEOCYSTOPLASTY

Abstract

You have accessJournal of UrologyPediatric Urology IV (MP51)1 Sep 2021MP51-14 INTERMEDIATE TO LONG TERM RENAL FUNCTIONAL OUTCOME IN PEDIATRIC PATIENTS WITH PREEXISTING CHRONIC KIDNEY DISEASE FOLLOWING ILEOCYSTOPLASTY Cody Savage, Sheila Mallenahalli, Pankaj Dangle, and David Joseph Cody SavageCody Savage More articles by this author , Sheila MallenahalliSheila Mallenahalli More articles by this author , Pankaj DanglePankaj Dangle More articles by this author , and David JosephDavid Joseph More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002077.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Ileocystoplasty is commonly performed to protect kidneys and increase bladder capacity. Though deterioration in renal function is observed in ∼ 15% patients, intermediate to long term effects of ileocystoplasty in patients with preexisting chronic kidney disease (CKD) are limited. This study aims to determine if ileocystoplasty in pediatric CKD patients is associated with further deterioration in renal function. METHODS: A retrospective chart review was performed of using inclusion criteria of patients ≤21 years undergoing ileocystoplasty from January 2006 to May 2020. Pre- and post-operative renal function (serum creatinine, eGFR) were collected and analyzed with descriptive statistics. RESULTS: Of 52 eligible patients, 23 patients had a prior diagnosis of CKD before undergoing ileocystoplasty, 4 of which later underwent renal transplant. The remaining 29 patients without preexisting CKD served as a control group (gp). The median pre-op sCr was 1.0 mg/dL in the CKD group, compared to 0.4 mg/dL in controls. The median post-operative (post-op), sCr was 0.9 mg/dL in the CKD group and 0.6 mg/dL in controls. The median pre-op and post op eGFR was 57.8 mL/min and 68.0 ml/min in CKD group and 119 mL/min and 106.8 ml/min in the control group respectively. Overall, 17% of controls had progression to CKD Stage 2 at a median follow up of 7.5 years. The median follow up time in CKD patients was 3.7 years (interquartile range 4.5 years) and 4.6 years in the control group (interquartile range 4.7 years). The median time from ileocystoplasty to transplant was 1.8 (interquartile range 1.0 years). The total median follow-up time in the transplant group was 6.7 (interquartile range 4.0 years). CONCLUSIONS: At intermediate follow-up, patients with pre-existing mild and moderate CKD have stable renal function following ileocystoplasty. About 17% of patients without pre-existing CKD had mild renal dysfunction following ileocystoplasty at 7-year follow-up. Source of Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e901-e902 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Cody Savage More articles by this author Sheila Mallenahalli More articles by this author Pankaj Dangle More articles by this author David Joseph More articles by this author Expand All Advertisement Loading ...